Clinical Trial of Solifenacin Versus Placebo Plus Pessary for Women With Vaginal Prolapse
Status:
Terminated
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effect of pessary therapy, with and without Solifenacin
(Vesicare), on symptoms of over active bladder and bladder function in women with overactive
bladder symptoms and pelvic organ prolapse.
Study Hypotheses:
Null hypothesis, HO: Reduction of anterior vaginal wall prolapse and treatment with
solifenacin does not improve overactive bladder symptoms more than reduction of anterior
vaginal wall prolapse and placebo.
Alternate hypothesis, HA: Reduction of anterior vaginal wall prolapse and treatment with
solifenacin does improve overactive bladder symptoms more than reduction of anterior vaginal
wall prolapse and placebo.